United States
Include All CSL Behring Country Sites

King of Prussia —

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is soliciting grants to support patient access to care through its Local Empowerment for Advocacy Development (LEAD) program. The LEAD program is committed to funding grassroots advocacy efforts in the United States by providing grants to patient organizations dedicated to helping people with rare diseases who use plasma-derived or recombinant therapies to manage their conditions.

"CSL Behring is proud to support patient organizations in their advocacy initiatives through LEAD grants," said Dennis Jackman, Senior Vice President, Public Affairs. "CSL Behring LEAD grants supplement existing resources to ensure that patient organizations are able to address complex legislative and public policy issues."

In the first round of grants, awarded in May and June of this year, CSL Behring gave more than $90,000 to seven patient advocacy organizations. These grants supported grassroots advocacy initiatives, including the development of state standards of care legislation, improving insurance access and mobilizing patient populations.

In order to qualify for a LEAD grant, an organization must be a recognized patient advocacy group representing individuals who use plasma/recombinant therapies to treat bleeding disorders, immune disorders, Alpha-1 deficiency or other conditions. The organization, which should either be planning to address an advocacy issue or currently addressing such an issue, must also be a non-profit with 501(c)(3) tax status.

LEAD grant applications must be received by October 31, 2008. Applications, specific criteria for applying, and additional information about the LEAD program are available on the CSL Behring Web site at www.cslbehring.com/leadgrants. The grants will be awarded to organizations demonstrating financial assistance is needed to accomplish important grassroots and state advocacy issues and initiatives.

About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring.com.

Patrick Collins

Christine Kuhinka

CRP16-05-0001 05/2016
© 2017 CSL Behring